Comparison

Mal-GGFG-PAB-MMAE European Partner

Item no. HY-170512-25mg
Manufacturer MedChem Express
CASRN 3055607-18-3
Amount 25 mg
Quantity options 1 ea 10 mg 25 mg 5 mg
Category
Type Crosslinkers
Specific against other
Purity 99.96
Citations [1]Huang J, et al., Highly stable targeted linker-drug conjugate. US20240293570.
Smiles O[C@@H](C1=CC=CC=C1)[C@@H](C)NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(OCC3=CC=C(C=C3)NC(CNC([C@@H](NC(CNC(CNC(CCN4C(C=CC4=O)=O)=O)=O)=O)CC5=CC=CC=C5)=O)=O)=O)=O)=O)=O)OC)=O
ECLASS 10.1 32170205
ECLASS 11.0 32170205
UNSPSC 41105316
Shipping Condition Cool pack
Available
Manufacturer - Type
ADC Related
Manufacturer - Applications
Cancer-programmed cell death
Manufacturer - Targets
Drug-Linker Conjugates for ADC
Shipping Temperature
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture and light)
Molecular Weight
1336.57
Product Description
Mal-GGFG-PAB-MMAE (Compound 8) is a drug-linker conjugate, which is composed of the mitotic inhibitor MMAE (HY-15162) and the linker Mal-GGFG-PAB. Mal-GGFG-PAB-MMAE can be used for synthesis of antibody-drug conjugate[1].
Manufacturer - Research Area
Cancer
Solubility
DMSO: ≥ 100 mg/mL
Manufacturer - Pathway
Antibody-drug Conjugate/ADC Related
Clinical information
No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 25 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close